Contribution
My Lords, I too am very grateful to the noble Baroness, Lady Deech, for securing this debate. As her debate focuses on the age of consent, there is a limited amount to be added to what has already been said by those who have spoken ahead of me. However, the debate does draw attention to an ongoing medical scandal of our times, which is the consent to drugs around which we have no evidence of safety. The noble Baroness, Lady Cass, for whom I have the highest of regard and esteem, and with whom I have discussed this subject with gratitude on multiple occasions, disagrees with me about the PATHWAYS puberty blockers trial. We agree on almost everything else. I think the nub of the debate lies there.
What I am hearing in the Chamber today is real concern about the age of children who are embarking on life-changing and possibly irreversible changes to their physical bodies: to their brain, to their bones, to their IQ and to their fertility. We just do not know whether the changes caused by use of puberty blockers in young people can be reversed. I hope I have read the review—the famous Cass Review—correctly. I hope so because I have read it several times; but when the noble Baroness refers to not withholding treatment, my understanding of that is that she means exploratory treatment, ensuring that the multiple reasons why children present in distress about their gender are fully explored and that they are given the opportunity to have the correct therapies and treatments for any of those issues.
There are comorbidities. A disproportionate number with gender distress are autistic, have mental health conditions or are in care. However, left alone, as the Cass review stated, most childhood gender distress resolves. In the largest follow-up study of 139 boys, most desisted, and a high proportion grew up to be gay or bisexual. Puberty blockers can prevent the child from processing their issues and their reasons. In the Tavistock’s own study, children embarked on puberty blockers went on to cross-sex hormones at a rate of 98%, almost the inverse of the resolution that takes place if puberty blockers are not taken. Therefore, we cannot set a safe age because no one has followed up on these young people. I appreciate and acknowledge that that is also something that the noble Baroness, Lady Cass, has highlighted and drawn attention to.
We have also seen an independent investigation by Professor Ellis into the WellBN clinic in Brighton, examining 78 children: 51 aged 16 and under given cross-sex hormones; four started at 12, four at 13, and more than two-thirds—53 of 78—had possible neurodevelopmental conditions. Capacity to consent was confirmed in only six cases out of 78; 22 children were prescribed without ever being seen face to face and 36 received prescriptions at their first appointment. That is not a treatment; that is a scandal—23 different prescribers were involved and one child lived more than 480 miles away. The NHS and the GMC were warned from at least 2020, but they failed to act.
The investigation is meant to have a second phase to review those children who are now adults, but that phase is on hold, and those young adults matter just as much. That data, the follow-up data, was withheld from the Cass review when it was trying to follow up on the children who had been treated at an earlier stage. The law was changed for that data-linkage study to be provided, and it still has not been. The law needs to compel it to be disclosed so we truly can establish what happens to these young people after these treatments.
The Levy review proposes moving more adult prescribing into GP-led services. That is the WellBN model, and it should not happen because we need to understand the scandal of this Wild West of medical treatment without meaningful consent before any further instances can take place, because there will be a cost to the NHS, as in the United States, where legal claims against the clinicians and the hospitals are now being brought.
I therefore use this opportunity to urge the Government to commission an independent inquiry into gender-related prescribing in primary care and in adult clinics, with a focus on those under 25.